Background. The effect of antihypertensive medications on cognitive function has not been well studied. The authors' objectives were to investigate the cross-sectional and longitudinal association between the use of antihypertensive medications and cognitive function and to compare different antihypertensive medication classes with regard to this association in an elderly population.
D
EMENTIA is a devastating illness that affects at least 4 million persons in the United States (1) . Although few treatments have been developed that would decrease the progression of this illness, prevention remains the most effective approach. Evidence from observational studies suggests that elevated blood pressure is a risk factor for cognitive impairment and the development of dementia (2) . In the Honolulu-Asia Aging Study, midlife higher systolic blood pressure was associated with an increased risk for late life poor cognitive function (3) . In addition, in a recent prospective population survey, high midlife systolic blood pressure was associated with an increased risk for Alzheimer's disease (AD) (4) . This association has been documented in different populations (5) (6) (7) (8) , in persons with and without cerebrovascular disease (9) , and in persons with AD (5, 10) . Interestingly, longitudinal surveys have suggested that blood pressure decreases in the period immediately preceding the onset of cognitive impairment (5) . The decline seen immediately before the onset of cognitive decline may explain the conflicting results seen in cross-sectional case control studies (9, (11) (12) (13) (14) (15) (16) .
It is possible, then, that pharmacologic measures to lower blood pressure may preserve function and decrease the risk for dementia. The evidence, however, has been conflicting. In 1987, Larson and colleagues (17) reported that persons who receive antihypertensive medications demonstrated global cognitive impairment. However, other cross-sectional and longitudinal studies have shown that use of antihypertensive medication is associated with preservation of cognitive function (8, 18, 19) . Randomized clinical trials have also found conflicting results. For example, in the Systolic Hypertension in the Elderly Program, no difference in cognitive decline or the onset of dementia occurred between treated and untreated participants (20) . In the Systolic Hypertension in Europe trial, however, treatment of hypertension was associated with a 50% decline in dementia incidence (21, 22) . These conflicting findings could be related, in part, to the use of different classes of antihypertensive medications. The comparative effect of the different classes of antihypertensive medications on cognition and dementia in the same population is not known.
In this study, our primary objective was to investigate the cross-sectional and longitudinal association between the use of antihypertensive medications and cognitive function in an elderly population. Our secondary objective was to compare different antihypertensive classes with regard to this association.
METHODS
We performed a cross-sectional and retrospective cohort study with repeated measures on a cohort of patients followed at the Palmetto Health Richland Senior Primary Care Practice, a community-based academic primary care geriatric practice in Columbia, South Carolina, founded in 1997. All practice physicians specialize in internal medicine (n ¼ 5) or family practice (n ¼ 1) and are fellowship-trained geriatricians. They provide diagnostic and therapeutic services to the participants and are responsible for the documentation of medical history in the patients' records. As part of the usual care provided in this practice, trained staff directly examine each patient's medication bottles during each visit. One day before their visit, patients are reminded by telephone to bring all their prescription and over-the-counter medication bottles with them. Staff members who are annually trained to measure blood pressure according to the American Heart Association standards measure patient blood pressure during each clinical encounter. All patients are offered yearly cognitive assessments via two standardized tools, the Mini-Mental Status Examination (MMSE) (23) and the Clock Draw Test (CDT) (24) , which are administered by trained geriatric social workers. Medical records are maintained in accordance with hospital requirements. We selected our participant sample serially (using the medical record numbers) from the overall Senior Primary Care Practice patients (n ¼ 2500). We included patients if they had been assessed with at least one cognitive test.
A medical student (S.S.) and a graduate student (H.C.) abstracted data from the initial and follow-up visits from the records. These data included the date of the visit, demographic and anthropometric information, sitting blood pressure measurements, educational level, family history, tobacco and alcohol use, clinical diagnoses, antihypertensive medication use, results of cognitive testing, and laboratory information including serum cholesterol and low-density and high-density lipoprotein levels. The database manager (R.B.) developed data extraction forms, and data entry was performed under the supervision of a geriatrician (I.H.). We considered that patients had hypertension if they were receiving antihypertensive medications or had a systolic blood pressure of 140 mmHg or greater or a diastolic blood pressure of 90 mmHg or greater. We considered patients to have treated hypertension if they were receiving any antihypertensive medication. We also abstracted dementia diagnosis and its subtypes, when available (AD and vascular dementia [VaD] ), from the records. We considered patients to have developed cognitive impairment if they had an MMSE score less than 24 or a clinical diagnosis of dementia at follow-up but not at baseline (25) . We performed cross-sectional analyses using data abstracted from the initial visit. We conducted longitudinal analyses, using data from the follow-up visits, only on those with more than one cognitive testing score.
We determined the patients' use of antihypertensive medications from the clinician's documentation, staff medication review, and written or called-in prescriptions. We separated drugs into nine classes: diuretics, angiotensinconverting enzyme inhibitors (ACE), beta-blockers (BB), alpha-blockers, angiotensin receptor blockers (ARB), dihydropyridine calcium channel blockers, non-dihydropyridine calcium channel blockers, clonidine, and others. We coded combination drugs individually as two separate antihypertensive classes. We assigned patients to each class if they were using the corresponding antihypertensive drug at baseline or during the follow-up period. In addition, we noted any change in antihypertensive class or the addition of a different antihypertensive class.
We performed multivariate analyses using the mixed model theory for repeated measures (26) (27) (28) . This procedure is used with unbalanced data, incorporates longitudinal change in predictor variables such as blood pressure, body mass index, age, and drug exposure, and is less likely to be affected by missing data (29) . The outcome measures we used were serial MMSE and CDT scores. We adjusted the multivariate models for the following covariates: age, sex, ethnicity, anthropometrics, diagnosis of stroke or diabetes mellitus during the follow-up period, serial blood pressure readings, cholesterol, low-density and high-density lipoprotein levels, baseline cognitive test results, alcohol and smoking history, level of education, and family history of dementia or AD. We used the mixed model to compare the rate of decline in cognitive scores in patients receiving and those not receiving antihypertensive medications. In addition, we evaluated the rate of cognitive decline in hypertensive patients using antihypertensive drugs versus those not using antihypertensive drugs, in patients with hypertension receiving antihypertensive medications versus those who were not hypertensive, and in patients with hypertension but not receiving antihypertensive medications versus those who did not have hypertension. We used logistic and multiple regression models for the crosssectional analyses with similar covariate adjustments. To adjust for the complexity of antihypertensive exposure, we performed analyses using an exposure index that measures the number of days each patient has used the antihypertensive medication class and incorporated that index in all the models. The institutional review board approved the study at the local institution.
RESULTS
We abstracted data on a convenience sample of 993 patients (mean age at baseline, 76.8 6 0.3 years; age range, 38-98 years [11 (1%) were younger than 60 years]; 74% women; 87% White, 11% African American) followed between 1997 and 2002 (the first evaluation was April 1, 1997; the last evaluation was July 1, 2002). Of those, 350 (mean age at baseline, 76.9 6 0.4 years; age range, 48-96 years; 73% women; 88% White, 11% African American) had serial cognitive testing and were included in the longitudinal analysis (mean follow-up, 24.9 6 0.7 months; follow-up range, 1-58.8 months, for a total of 724 6 20 patient-years).
At baseline, 81% patients had hypertension and 54% were receiving antihypertensive medications. In addition, at baseline 213 (24%) patients had clinical diagnoses of dementia (66% AD, 10% VaD), and during the follow-up period, we identified 62 new cases of cognitive impairment. Treated patients were older (p , .05); had higher mean body mass indexes (p , .05); and had a higher prevalence of diabetes mellitus (p , .05) and stroke (p , .05), and lower mean cholesterol level (p , .05) ( Table 1) . Of those patients taking antihypertensive medications, 297 (54.9%) were receiving one, 183 (33.8%) were receiving two, and 61 (11.3%) were receiving three or more antihypertensive classes (Table 2 ).
In the cross-sectional analysis, we found no difference in mean MMSE score, CDT score, or diagnosis of dementia, AD, or VaD between those receiving and those who were not receiving antihypertensive medications (Table 1 ). In addition, we observed no differences between nonhypertensive and hypertensive patients who were receiving or not receiving medications (mean MMSE score, 23.9 6 0.6 vs 24.9 6 0.5 vs 25. 7] in nonhypertensive patients and in hypertensive patients receiving antihypertensive medications and those not receiving antihypertensive medications, respectively). When we compared the different antihypertensive classes, none was associated with cognitive impairment or risk for dementia, AD, or VaD (Table 2) .
In the longitudinal analysis, we found that patients who were receiving antihypertensive medications had a lower rate of decline in cognitive function compared with patients who were not receiving antihypertensive medications. At the last visit, patients receiving antihypertensive medications showed a decline of À0.8 6 2 points vs À5.8 6 2.5 points in patients not receiving antihypertensive medications (p ¼ .007) (Figure 1) . Compared with the first visit, treated hypertensive patients at the last visit showed a decline of À0.6 6 0.8 points on the MMSE scale compared with a decline of À4.5 6 1.8 points in hypertensive patients who were not receiving antihypertensive medications (p ¼ .0004) and À5.9 6 2.4 in nonhypertensive patients (p ¼ .02). We found no differences in the decline of MMSE scores between nonhypertensive and hypertensive patients who were not receiving medications (p ¼ .4). Treated hypertensive patients also had a lower decline in their CDT scores compared with the other groups (decline of À0.3 6 0.8 points in those taking antihypertensive medications vs À2.2 6 0.8 points in those who were not taking antihypertensive medications [p ¼ .002]). We noted a similar pattern in those with and without dementia at baseline and in those with AD (p , .0001, p , .0001, and p ¼ .015 for the difference in cognitive decline on the MMSE in those with and without dementia and with AD at baseline, respectively) ( Figure 1 
DISCUSSION
We found that the use of antihypertensive medications may be associated with a decreased risk for the development of cognitive impairment in a population of older adults followed at a primary care practice. This effect is independent of baseline cognitive function and blood pressure level, and it is present in persons with a clinical diagnosis of dementia or AD. In addition, this study suggests that diuretics, ACE, ARB, and BB are the antihypertensive classes that may be associated with this lower risk. Furthermore, our data suggest that the use of ARB may even lead to improved cognitive function.
Recently, Murray and colleagues (19) reported that the use of antihypertensive medications in an African American elderly population was associated with a risk reduction of 38% in cognitive impairment, a reduction similar to our result in the current study. Investigators noted similar trends in the Kungsholmen project (OR, 0.6; 95% CI, 0.3 to 1.2) and in the Rotterdam study (OR, 0.76; 95% CI, 0.52 to 1.12); however, the risk reduction was not statistically significant (30, 31) . Our study, however, adds the evidence that this association is present in persons with a preexisting dementia illness, including AD, and in persons with intact cognitive function. We found this association in the longitudinal but not the cross-sectional analysis at baseline, which suggests that the association is not related to patient selection for antihypertensive treatment. Also at baseline, we found no difference in cognitive scores between persons who were receiving or not receiving antihypertensive medications. We also adjusted all models for baseline cognitive function to minimize the effect of this potential selection bias.
Our study suggests that patients using diuretics and BB have a lower rate of decline in cognitive testing scores. Previous reports about the effect of diuretics and BB on cognition have been conflicting (20, 32) . For example in the Systolic Hypertension in the Elderly Program, in which participants were treated with a diuretic or a BB, the investigators found no difference between treated and untreated participants on various cognitive measures (20, 32) . In contrast, in 1999 Guo and colleagues (30) reported that dementia was less likely to develop in participants using diuretics. The difference in these studies is likely related to the study population and the cognitive tests used. Although our sample size for the longitudinal analysis was relatively small, the current study supports the evidence that the use of diuretics or BB is associated with a lower rate of cognitive decline. Furthermore, diuretic use was associated with a lower incidence of cognitive impairment.
Animal models and observational studies have suggested a role of the renin-angiotensin system in cognition and dementia (33) (34) (35) . For example, patients with AD have an increased frequency of angiotensin-converting enzyme I allele (36) and an increased density of angiotensinconverting enzyme in the temporal cortex (37) . The number of studies assessing the effect of ACE on cognition is small (38) . Our study suggests that ACE can provide protection against cognitive decline independent of cerebrovascular disease. Evidence about the effect of ARB on cognition is also scarce (34) . A recent clinical trial showed that the use of an ARB agent was associated with increased MMSE scores (p , .001) compared with a thiazide diuretic (39) . Our study suggests that the use of ARB is associated with improved cognitive function. If this finding is confirmed on a larger scale, ARB could potentially provide an additional means of therapy for persons with existing cognitive impairment. We found no association between calcium channel blockers or Notes: *Change is the difference between first and last visit was derived from the overall models and is adjusted for covariates. y p value is from the mixed model testing the hypothesis of the difference in cognitive decline rates between those using versus those not using the specific antihypertensive class. Except in the nonhypertensives and those not on antihypertensives, p value is for the rate of decline over the follow-up period in that group.
alpha-blockers and cognitive impairment. Previous clinical trials have found a protective effect of a dihydropyridine calcium channel blocker, which is not currently used in the United States, against cognitive impairment (22) . We have found that persons using clonidine show a greater decline in their cognitive function. This finding, although in agreement with previous reports (17, 40) , should be interpreted cautiously because of the small number of patients in our sample who were taking clonidine.
A limitation of our study was our inability to confirm drug exposure. We reviewed medications listed on patients' charts to assess current antihypertensive exposure and confirmed the medical record lists with providers' documentation and written prescriptions to increase reliability. In addition, we could not assess past exposure to antihypertensive medications.
Another limitation of our study is that serial cognitive testing may occur more frequently in those patients demonstrating cognitive impairment. However, this would be true for both those receiving and those not receiving antihypertensive medications and thus would not affect our comparisons. Furthermore, this was an observational study and exposure to antihypertensive medications was not randomized. It is possible that persons who show cognitive impairment are less likely to be prescribed antihypertensive medications in the first place. However, this would have a minimal effect on our findings because baseline cognitive function was similar between those patients receiving and those not receiving antihypertensive medications.
The smaller sample size of the longitudinal group represents another limitation. The characteristics of the longitudinal sample were similar to those of the crosssectional sample, suggesting that this limitation would have a small effect on our results. Because of the relatively small sample size, the results of the multiple comparisons ( Figure  1B ) among nonhypertensive patients, hypertensive patients receiving medications, and hypertensive patients not receiving medications need to be interpreted cautiously. The results of our longitudinal analysis need to be confirmed by randomized clinical trials.
Conclusions
Until a clinical trial testing the effect of the different classes of antihypertensive medications on cognition in older adults is conducted, most of our evidence will depend on observational studies. In this study, we found that in older patients, including those with dementia and AD, and those using diuretics, ACE, BB, and ARB may provide protection against progressive cognitive decline. In addition, this study suggests that use of an ARB may even be associated with cognitive improvement. Studies to confirm our findings are urgently needed. If confirmed, our finding will have considerable economic and public health effects.
